WSO - March 2024 - 309

Nguyen et al.
309
Table 1. Baseline characteristics of patients in the over 24 h and 6- to 24-h groups.
All (n = 166)
Age, median (SD)
Female sex-no. (%)
NIHSS
Median (IQR)
Range
Prior tPA (%)
Type of onset:
Wake-up stroke, n (%)
Unwitnessed onset, n (%)
Witnessed onset, n (%)
Hypertension (%)
Diabetes (%)
AF (%)
History of antithrombotic therapy (%, n = 164)
ASPECTS
Median (IQR)
Core (IQR) mL
Mismatch (IQR) mL
Mismatch ratio (IQR)
Hypoperfusion index (HIR)
Good collaterals (%)
Occlusion sites (%)
ICA
M1
Tandem
TOAST
Cardioembolic (%)
Large vessel (%)
Other and undetermined (%)
Malignant brain edema
Onset-to-arrival (IQR) (h)
Door-to-perfusion imaging (IQR) (min)
Perfusion imaging-to-groin (IQR) (min)
Door-to-groin (IQR) (min)
Groin-to-revascularization (min)
Onset-to-groin (IQR) (h)
28 (16.9)
88 (53.0)
50 (30.1)
13 (7.83)
10.8 (7.89-15.1)
161 (121-244)
75.0 (53.0-109)
249 (192-348)
65.0 (55.0-90.0)
15.3 (12.1-20.5)
2 (10.0)
12 (60.0)
6 (30.0)
0 (0)
21.5 (19.0-23.7)
267 (172.0-388.0)
72.5 (56.2-83.2)
352 (231-480)
70.0 (52.5-85.0)
27.2 (25.7-30.9)
26 (17.8)
76 (52.1)
44 (30.1)
13 (8.9)
0.764
0.37
10.2 (7.48-13.8) <0.001
156 (113.0-212.0) 0.001
76.0 (53.0-109.0)
245 (188-324)
65.0 (55.0-90.0)
0.77
0.008
0.88
14.3 (11.9-18.9) <0.001
SD: standard deviation; NIHSS: National Institutes of Health Stroke Scale; IQR: interquartile range; ASPECTS: Alberta Stroke Program Early CT
Score; ICA: internal carotid artery; tPA: tissue plasminogen activator; AF: atrial fibrillation; TOAST: Trial of ORG 10172 in acute stroke treatment.
International Journal of Stroke, 19(3)
63.0 (56.0-69.0)
48 (28.9)
14.5 (10.0-18.0)
6-25
8 (4.82)
77 (46.4)
18 (10.8)
71 (42.8)
143 (86.1)
30 (18.1)
29 (17.5)
29 (17.7)
8.0 (8.0-9.0)
9.0 (3.0-22.0)
96.0 (62.5-138.0)
7.1 (3.68-12.9)
0.27 (0.12-0.45)
111 (66.9)
58 (34.9)
94 (56.6)
14 (8.5)
Symptom onset
>24 h (n = 20)
60.0 (54.0-68.0)
3 (15.0)
12.0 (10.0-18.0)
6-25
0 (0)
10 (50.0)
3 (15.0)
7 (35.0)
17 (85)
4 (20.0)
2 (10.0)
1 (5.0)
8.0 (8.0-9.5)
11.0 (0.0-24.8)
106.0 (55.8-196.0)
6.46 (3.80-14.2)
0.21 (0.08-0.39)
15 (75.0)
11 (55.0)
6 (30.0)
3 (15.0)
Symptom onset
6-24 h (n = 146)
63.5 (56.2-70.0)
45 (30.8)
15.0 (11.0-18.8)
6-25
8 (6.45)
67 (45.9)
15 (10.3)
64 (43.8)
126 (86.3)
26 (17.8)
27 (18.5)
28 (19.4)
8.0 (7.0-9.0)
9.0 (0.0-20.8)
96.0 (64.0-133.0)
7.24 (3.73-12.8)
0.28 (0.13-0.46)
96 (65.8)
47 (32.2)
88 (60.3)
11 (7.53)
p
0.28
0.143
0.37
0.60
0.58
>0.999
0.76
0.53
0.206
0.031
0.864
0.44
0.911
0.205
0.41
0.028

WSO - March 2024

Table of Contents for the Digital Edition of WSO - March 2024

Contents
WSO - March 2024 - Cover1
WSO - March 2024 - Cover2
WSO - March 2024 - 245
WSO - March 2024 - Contents
WSO - March 2024 - 247
WSO - March 2024 - 248
WSO - March 2024 - 249
WSO - March 2024 - 250
WSO - March 2024 - 251
WSO - March 2024 - 252
WSO - March 2024 - 253
WSO - March 2024 - 254
WSO - March 2024 - 255
WSO - March 2024 - 256
WSO - March 2024 - 257
WSO - March 2024 - 258
WSO - March 2024 - 259
WSO - March 2024 - 260
WSO - March 2024 - 261
WSO - March 2024 - 262
WSO - March 2024 - 263
WSO - March 2024 - 264
WSO - March 2024 - 265
WSO - March 2024 - 266
WSO - March 2024 - 267
WSO - March 2024 - 268
WSO - March 2024 - 269
WSO - March 2024 - 270
WSO - March 2024 - 271
WSO - March 2024 - 272
WSO - March 2024 - 273
WSO - March 2024 - 274
WSO - March 2024 - 275
WSO - March 2024 - 276
WSO - March 2024 - 277
WSO - March 2024 - 278
WSO - March 2024 - 279
WSO - March 2024 - 280
WSO - March 2024 - 281
WSO - March 2024 - 282
WSO - March 2024 - 283
WSO - March 2024 - 284
WSO - March 2024 - 285
WSO - March 2024 - 286
WSO - March 2024 - 287
WSO - March 2024 - 288
WSO - March 2024 - 289
WSO - March 2024 - 290
WSO - March 2024 - 291
WSO - March 2024 - 292
WSO - March 2024 - 293
WSO - March 2024 - 294
WSO - March 2024 - 295
WSO - March 2024 - 296
WSO - March 2024 - 297
WSO - March 2024 - 298
WSO - March 2024 - 299
WSO - March 2024 - 300
WSO - March 2024 - 301
WSO - March 2024 - 302
WSO - March 2024 - 303
WSO - March 2024 - 304
WSO - March 2024 - 305
WSO - March 2024 - 306
WSO - March 2024 - 307
WSO - March 2024 - 308
WSO - March 2024 - 309
WSO - March 2024 - 310
WSO - March 2024 - 311
WSO - March 2024 - 312
WSO - March 2024 - 313
WSO - March 2024 - 314
WSO - March 2024 - 315
WSO - March 2024 - 316
WSO - March 2024 - 317
WSO - March 2024 - 318
WSO - March 2024 - 319
WSO - March 2024 - 320
WSO - March 2024 - 321
WSO - March 2024 - 322
WSO - March 2024 - 323
WSO - March 2024 - 324
WSO - March 2024 - 325
WSO - March 2024 - 326
WSO - March 2024 - 327
WSO - March 2024 - 328
WSO - March 2024 - 329
WSO - March 2024 - 330
WSO - March 2024 - 331
WSO - March 2024 - 332
WSO - March 2024 - 333
WSO - March 2024 - 334
WSO - March 2024 - 335
WSO - March 2024 - 336
WSO - March 2024 - 337
WSO - March 2024 - 338
WSO - March 2024 - 339
WSO - March 2024 - 340
WSO - March 2024 - 341
WSO - March 2024 - 342
WSO - March 2024 - 343
WSO - March 2024 - 344
WSO - March 2024 - 345
WSO - March 2024 - 346
WSO - March 2024 - 347
WSO - March 2024 - 348
WSO - March 2024 - 349
WSO - March 2024 - 350
WSO - March 2024 - 351
WSO - March 2024 - 352
WSO - March 2024 - 353
WSO - March 2024 - 354
WSO - March 2024 - 355
WSO - March 2024 - 356
WSO - March 2024 - 357
WSO - March 2024 - 358
WSO - March 2024 - 359
WSO - March 2024 - 360
WSO - March 2024 - 361
WSO - March 2024 - 362
WSO - March 2024 - 363
WSO - March 2024 - 364
WSO - March 2024 - 365
WSO - March 2024 - 366
WSO - March 2024 - 367
WSO - March 2024 - 368
WSO - March 2024 - 369
WSO - March 2024 - 370
WSO - March 2024 - 371
WSO - March 2024 - 372
WSO - March 2024 - Cover3
WSO - March 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com